

# Opravný list k bakalářské práci

Rekombinantní příprava DNA vazebné domény transkripčního faktoru TEAD1 pro studium jeho interakcí s DNA

Veronika Kúdelová

Praha 2019

## Strana 54 až 57: doplnění a sjednocení použité literatury

- (1) Xiao, J. H.; Davidson, I.; Ferrandon, D.; Rosales, R.; Vigneron, M.; Macchi, M.; Ruffenach, F.; Chambon, P. One cell-specific and three ubiquitous nuclear proteins bind in vitro to overlapping motifs in the domain Bi of the SV40 enhancer. *EMBO J.* **1987**, *6* (10), 3005–3013.
- (2) Xiao, J. H.; Davidson, I.; Matthes, H.; Garnier, J. M.; Chambon, P. Cloning, expression, and transcriptional properties of the human enhancer factor TEF-1. *Cell* **1991**, *65* (4), 551–568.
- (3) Andrianopoulos, A.; Timberlake, W. E. ATTS, a new and conserved DNA binding domain. *Plant Cell* **1991**, *3* (8), 747–748.
- (4) Liu, F.; Wang, X.; Hu, G.; Wang, Y.; Zhou, J. The transcription factor TEAD1 represses smooth muscle-specific gene expression by abolishing myocardin function. *J. Biol. Chem.* **2014**, *289* (6), 3308–3316.
- (5) Jacquemin, P.; Hwang, J. J.; Martial, J. A.; Dollé, P.; Davidson, I. A novel family of developmentally regulated mammalian transcription factors containing the TEA/ATTS DNA binding domain. *J. Biol. Chem.* **1996**, *271* (36), 21775–21785.
- (6) Landin-Malt, A.; Benhaddou, A.; Zider, A.; Flagiello, D. An evolutionary, structural and functional overview of the mammalian TEAD1 and TEAD2 transcription factors. *Gene* **2016**, *591* (1), 292–303.
- (7) Kaneko, K. J.; DePamphilis, M. L. Regulation of gene expression at the beginning of mammalian development and the TEAD family of transcription factors. *Dev. Genet.* **1998**, *22* (1), 43–55.
- (8) Yoshida, T. MCAT Elements and the TEF-1 Family of Transcription Factors in Muscle Development and Disease. *Arterioscler. Thromb. Vasc. Biol.* **2008**, *28* (1), 8–17.
- (9) Wang, Q.; Latham, K. E. Translation of maternal messenger ribonucleic acids encoding transcription factors during genome activation in early mouse embryos. *Biol. Reprod.* **2000**, *62* (4), 969–978.
- (10) Kaneko, K. J.; Cullinan, E. B.; Latham, K. E.; DePamphilis, M. L. Transcription factor mTEAD-2 is selectively expressed at the beginning of zygotic gene expression in the mouse. *Development* **1997**, *124* (10), 1963–1973.
- (11) Zhou, Y.; Huang, T.; Cheng, A. S. L.; Yu, J.; Kang, W.; To, K. F. The TEAD Family and Its Oncogenic Role in Promoting Tumorigenesis. *Int. J. Mol. Sci.* **2016**, *17* (1), 138.
- (12) Milewski, R. C.; Chi, N. C.; Li, J.; Brown, C.; Lu, M. M.; Epstein, J. A. Identification of minimal enhancer elements sufficient for Pax3 expression in neural crest and implication of Tead2 as a regulator of Pax3. *Development* **2004**, *131* (4), 829–837.
- (13) Pobbati, A. V.; Hong, W. Emerging roles of TEAD transcription factors and its coactivators in cancers. *Cancer Biol. Ther.* **2013**, *14* (5), 390–398.
- (14) Chen, Z.; Friedrich, G. A.; Soriano, P. Transcriptional enhancer factor 1 disruption by a retroviral gene trap leads to heart defects and embryonic lethality in mice. *Genes Dev.* **1994**, *8* (19), 2293–2301.
- (15) Sawada, A.; Kiyonari, H.; Ukita, K.; Nishioka, N.; Imuta, Y.; Sasaki, H. Redundant roles of Tead1 and Tead2 in notochord development and the regulation of cell proliferation and survival. *Mol. Cell. Biol.* **2008**, *28* (10), 3177–3189.

- (16) Jacquemin, P.; Sapin, V.; Alsat, E.; Evain-Brion, D.; Dollé, P.; Davidson, I. Differential expression of the TEF family of transcription factors in the murine placenta and during differentiation of primary human trophoblasts in vitro. *Dev. Dyn.* **1998**, *212* (3), 423–436.
- (17) Holden, J. K.; Cunningham, C. N. Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors. *Cancers (Basel)*. **2018**, *10* (3), 81.
- (18) Yagi, R.; Kohn, M. J.; Karavanova, I.; Kaneko, K. J.; Vullhorst, D.; DePamphilis, M. L.; Buonanno, A. Transcription factor TEAD4 specifies the trophectoderm lineage at the beginning of mammalian development. *Development* **2007**, *134* (21), 3827–3836.
- (19) Mahoney, W. M.; Hong, J.-H.; Yaffe, M. B.; Farrance, I. K. G.; Farrance, I. K. G. The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members. *Biochem. J.* **2005**, *388* (Pt 1), 217–225.
- (20) Vassilev, A.; Kaneko, K. J.; Shu, H.; Zhao, Y.; DePamphilis, M. L. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. *Genes Dev.* **2001**, *15* (10), 1229–1241.
- (21) Li, Z.; Zhao, B.; Wang, P.; Chen, F.; Dong, Z.; Yang, H.; Guan, K.-L.; Xu, Y. Structural insights into the YAP and TEAD complex. *Genes Dev.* **2010**, *24* (3), 235–240.
- (22) Tian, W.; Yu, J.; Tomchick, D. R.; Pan, D.; Luo, X. Structural and functional analysis of the YAP-binding domain of human TEAD2. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, *107* (16), 7293–7298.
- (23) Chen, L.; Loh, P. G.; Song, H. Structural and functional insights into the TEAD-YAP complex in the Hippo signaling pathway. *Protein Cell* **2010**, *1* (12), 1073–1083.
- (24) Anbanandam, A.; Albarado, D. C.; Nguyen, C. T.; Halder, G.; Gao, X.; Veeraraghavan, S. Insights into transcription enhancer factor 1 (TEF-1) activity from the solution structure of the TEA domain. *Proc. Natl. Acad. Sci. U. S. A.* **2006**, *103* (46), 17225–17230.
- (25) Lee, D.-S.; Vonrhein, C.; Albarado, D.; Raman, C. S.; Veeraraghavan, S. A potential structural switch for regulating DNA-binding by TEAD transcription factors. *J Mol Biol* **2016**, *428* (12), 2557–2568.
- (26) Shi, Z.; He, F.; Chen, M.; Hua, L.; Wang, W.; Jiao, S.; Zhou, Z. DNA-binding mechanism of the Hippo pathway transcription factor TEAD4. *Oncogene* **2017**, *36* (30), 4362–4369.
- (27) Farrance, I. K.; Mar, J. H.; Ordahl, C. P. M-CAT binding factor is related to the SV40 enhancer binding factor, TEF-1. *J. Biol. Chem.* **1992**, *267* (24), 17234–17240.
- (28) Mar, J. H.; Ordahl, C. P. M-CAT binding factor, a novel trans-acting factor governing muscle-specific transcription. *Mol. Cell. Biol.* **1990**, *10* (8), 4271–4283.
- (29) Carlini, L. E.; Getz, M. J.; Strauch, A. R.; Kelm, R. J. Cryptic MCAT enhancer regulation in fibroblasts and smooth muscle cells. Suppression of TEF-1 mediated activation by the single-stranded DNA-binding proteins, Pur alpha, Pur beta, and MSY1. *J. Biol. Chem.* **2002**, *277* (10), 8682–8692.
- (30) Khan, A.; Fornes, O.; Stigliani, A.; Gheorghe, M.; Castro-Mondragon, J. A.; van der Lee, R.; Bessy, A.; Chèneby, J.; Kulkarni, S. R.; Tan, G. JASPAR 2018: update of the open-access database of transcription factor binding profiles and its web framework. *Nucleic Acids Res.* **2018**, *46* (D1), D260–D266.
- (31) Noland, C. L.; Gierke, S.; Schnier, P. D.; Murray, J.; Sandoval, W. N.; Sagolla, M.; Dey, A.; Hannoush, R. N.; Fairbrother, W. J.; Cunningham, C. N. Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling. *Structure* **2016**, *24* (1), 179–186.
- (32) Chan, P.; Han, X.; Zheng, B.; DeRan, M.; Yu, J.; Jarugumilli, G. K.; Deng, H.; Pan, D.; Luo, X.; Wu, X. Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway. *Nat. Chem. Biol.* **2016**, *12* (4), 282–289.
- (33) Gibault, F.; Sturbaut, M.; Bailly, F.; Melnyk, P.; Cotellet, P. Targeting Transcriptional Enhanced Associate Domains (TEADs). *J. Med. Chem.* **2018**, *61* (12), 5057–5072.

- (34) Zhu, C.; Li, L.; Zhao, B. The regulation and function of YAP transcription co-activator. *Acta Biochim. Biophys. Sin. (Shanghai)*. **2015**, *47* (1), 16–28.
- (35) Crawford, J. J.; Bronner, S. M.; Zbieg, J. R. Hippo pathway inhibition by blocking the YAP/TAZ–TEAD interface: a patent review. *Expert Opin. Ther. Pat.* **2018**, *28* (12), 867–873.
- (36) Chen, H. I.; Sudol, M. The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. *Proc. Natl. Acad. Sci. U. S. A.* **1995**, *92* (17), 7819–7823.
- (37) Oka, T.; Sudol, M. Nuclear localization and pro-apoptotic signaling of YAP2 require intact PDZ-binding motif. *Genes to Cells* **2009**, *14* (5), 607–615.
- (38) Komuro, A.; Nagai, M.; Navin, N. E.; Sudol, M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. *J. Biol. Chem.* **2003**, *278* (35), 33334–33341.
- (39) Oka, T.; Remue, E.; Meerschaert, K.; Vanloo, B.; Boucherie, C.; Gfeller, D.; Bader, G. D.; Sidhu, S. S.; Vandekerckhove, J.; Gettemans, J. Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. *Biochem. J.* **2010**, *432* (3), 461–472.
- (40) Kanai, F.; Marignani, P. A.; Sarbassova, D.; Yagi, R.; Hall, R. A.; Donowitz, M.; Hisaminato, A.; Fujiwara, T.; Ito, Y.; Cantley, L. C. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. *EMBO J.* **2000**, *19* (24), 6778–6791.
- (41) Kaan, H. Y. K.; Chan, S. W.; Tan, S. K. J.; Guo, F.; Lim, C. J.; Hong, W.; Song, H. Crystal structure of TAZ–TEAD complex reveals a distinct interaction mode from that of YAP–TEAD complex. *Sci. Rep.* **2017**, *7* (1), 2035.
- (42) Vaudin, P.; Delanoue, R.; Davidson, I.; Silber, J.; Zider, A. TONDU (TDU), a novel human protein related to the product of vestigial (vg) gene of *Drosophila melanogaster* interacts with vertebrate TEF factors and substitutes for Vg function in wing formation. *Development* **1999**, *126* (21), 4807–4816.
- (43) Zhang, W.; Gao, Y.; Li, P.; Shi, Z.; Guo, T.; Li, F.; Han, X.; Feng, Y.; Zheng, C.; Wang, Z. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP–TEAD transcriptional complex. *Cell Res.* **2014**, *24* (3), 331–343.
- (44) Zhao, B.; Ye, X.; Yu, J.; Li, L.; Li, W.; Li, S.; Yu, J.; Lin, J. D.; Wang, C.-Y.; Chinnaiyan, A. M. TEAD mediates YAP-dependent gene induction and growth control. *Genes Dev.* **2008**, *22* (14), 1962–1971.
- (45) Creemers, E. E.; Sutherland, L. B.; McAnally, J.; Richardson, J. A.; Olson, E. N. Myocardin is a direct transcriptional target of Mef2, Tead and Foxo proteins during cardiovascular development. *Development* **2006**, *133* (21), 4245–4256.
- (46) Watt, K. I.; Turner, B. J.; Hagg, A.; Zhang, X.; Davey, J. R.; Qian, H.; Beyer, C.; Winbanks, C. E.; Harvey, K. F.; Gregorevic, P. The Hippo pathway effector YAP is a critical regulator of skeletal muscle fibre size. *Nat. Commun.* **2015**, *6* (1), 6048.
- (47) Schütte, U.; Bisht, S.; Heukamp, L. C.; Kebschull, M.; Florin, A.; Haarmann, J.; Hoffmann, P.; Bendas, G.; Buettner, R.; Brossart, P. Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma. *Transl. Oncol.* **2014**, *7* (2), 309–321.
- (48) Xia, Y.; Zhang, Y.-L.; Yu, C.; Chang, T.; Fan, H.-Y. YAP/TEAD Co-Activator Regulated Pluripotency and Chemoresistance in Ovarian Cancer Initiated Cells. *PLoS One* **2014**, *9* (11), e109575.
- (49) Chu, C.-Y.; Chang, C.-C.; Prakash, E.; Kuo, M.-L. Connective tissue growth factor (CTGF) and cancer progression. *J. Biomed. Sci.* **2008**, *15* (6), 675–685.
- (50) Lai, D.; Ho, K. C.; Hao, Y.; Yang, X. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. *Cancer Res.* **2011**, *71* (7), 2728–2738.

- (51) Xu, M. Z.; Chan, S. W.; Liu, A. M.; Wong, K. F.; Fan, S. T.; Chen, J.; Poon, R. T.; Zender, L.; Lowe, S. W.; Hong, W. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. *Oncogene* **2011**, *30* (10), 1229–1240.
- (52) Shoyab, M.; McDonald, V. L.; Bradley, J. G.; Todaro, G. J. Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. *Proc. Natl. Acad. Sci. U. S. A.* **1988**, *85* (17), 6528–6532.
- (53) Zhang, J.; Ji, J.-Y.; Yu, M.; Overholtzer, M.; Smolen, G. A.; Wang, R.; Brugge, J. S.; Dyson, N. J.; Haber, D. A. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. *Nat. Cell Biol.* **2009**, *11* (12), 1444–1450.
- (54) Liu, Y.; Wang, G.; Yang, Y.; Mei, Z.; Liang, Z.; Cui, A.; Wu, T.; Liu, C.-Y.; Cui, L. Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial–mesenchymal transition and metastasis in a YAP-independent manner. *Oncogene* **2016**, *35* (21), 2789–2800.
- (55) Landin Malt, A.; Cagliero, J.; Legent, K.; Silber, J.; Zider, A.; Flagiello, D. Alteration of TEAD1 expression levels confers apoptotic resistance through the transcriptional up-regulation of Livin. *PLoS One* **2012**, *7* (9), e45498.
- (56) Kim, M.; Kim, T.; Johnson, R. L.; Lim, D.-S. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ. *Cell Rep.* **2015**, *11* (2), 270–282.
- (57) Zhao, P.; Caretti, G.; Mitchell, S.; McKeehan, W. L.; Boskey, A. L.; Pachman, L. M.; Sartorelli, V.; Hoffman, E. P. Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway. *J. Biol. Chem.* **2006**, *281* (1), 429–438.
- (58) Udan, R. S.; Kango-Singh, M.; Nolo, R.; Tao, C.; Halder, G. Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. *Nat. Cell Biol.* **2003**, *5* (10), 914–920.
- (59) Yu, F.-X.; Zhao, B.; Guan, K.-L. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. *Cell* **2015**, *163* (4), 811–828.
- (60) Moon, S.; Yeon Park, S.; Woo Park, H. Regulation of the Hippo pathway in cancer biology. *Cell. Mol. Life Sci.* **2018**, *75* (13), 2303–2319.
- (61) Zhao, B.; Li, L.; Tumaneng, K.; Wang, C.-Y.; Guan, K.-L. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). *Genes Dev.* **2010**, *24* (1), 72–85.
- (62) Moroishi, T.; Hansen, C. G.; Guan, K.-L. The emerging roles of YAP and TAZ in cancer. *Nat. Rev. Cancer* **2015**, *15* (2), 73–79.
- (63) Zhao, B.; Li, L.; Lu, Q.; Wang, L. H.; Liu, C.-Y.; Lei, Q.; Guan, K.-L. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. *Genes Dev.* **2011**, *25* (1), 51–63.
- (64) Zhang, N.; Bai, H.; David, K. K.; Dong, J.; Zheng, Y.; Cai, J.; Giovannini, M.; Liu, P.; Anders, R. A.; Pan, D. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. *Dev. Cell* **2010**, *19* (1), 27–38.
- (65) Ota, M.; Sasaki, H. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling. *Development* **2008**, *135* (24), 4059–4069.
- (66) Yu, F.-X.; Zhang, Y.; Park, H. W.; Jewell, J. L.; Chen, Q.; Deng, Y.; Pan, D.; Taylor, S. S.; Lai, Z.-C.; Guan, K.-L. Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. *Genes Dev.* **2013**, *27* (11), 1223–1232.
- (67) DeRan, M.; Yang, J.; Shen, C.-H.; Peters, E. C.; Fitamant, J.; Chan, P.; Hsieh, M.; Zhu, S.; Asara, J. M.; Zheng, B. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. *Cell Rep.* **2014**, *9* (2), 495–503.
- (68) Liu-Chittenden, Y.; Huang, B.; Shim, J. S.; Chen, Q.; Lee, S.-J.; Anders, R. A.; Liu, J. O.; Pan, D. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. *Genes Dev.* **2012**, *26* (12), 1300–1305.

- (69) Wang, C.; Zhu, X.; Feng, W.; Yu, Y.; Jeong, K.; Guo, W.; Lu, Y.; Mills, G. B. Verteporfin inhibits YAP function through up-regulating 14-3-3 $\sigma$  sequestering YAP in the cytoplasm. *Am. J. Cancer Res.* **2016**, *6* (1), 27–37.
- (70) Jiao, S.; Wang, H.; Shi, Z.; Dong, A.; Zhang, W.; Song, X.; He, F.; Wang, Y.; Zhang, Z.; Wang, W. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. *Cancer Cell* **2014**, *25* (2), 166–180.
- (71) Zhang, Z.; Lin, Z.; Zhou, Z.; Shen, H. C.; Yan, S. F.; Mayweg, A. V; Xu, Z.; Qin, N.; Wong, J. C.; Zhang, Z. Structure-Based Design and Synthesis of Potent Cyclic Peptides Inhibiting the YAP-TEAD Protein-Protein Interaction. *ACS Med. Chem. Lett.* **2014**, *5* (9), 993–998.
- (72) Pobbati, A. V; Han, X.; Hung, A. W.; Weiguang, S.; Huda, N.; Chen, G.-Y.; Kang, C.; San, C.; Chia, B.; Luo, X. Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy HHS Public Access. *Structure* **2015**, *23* (11), 2076–2086.
- (73) Sharon, E.; Kalma, Y.; Sharp, A.; Raveh-Sadka, T.; Levo, M.; Zeevi, D.; Keren, L.; Yakhini, Z.; Weinberger, A.; Segal, E. Inferring gene regulatory logic from high-throughput measurements of thousands of systematically designed promoters. *Nat. Biotechnol.* **2012**, *30* (6), 521–530.
- (74) Lorenzin, F.; Benary, U.; Baluapuri, A.; Walz, S.; Jung, L. A.; von Eyss, B.; Kisker, C.; Wolf, J.; Eilers, M.; Wolf, E. Different promoter affinities account for specificity in MYC-dependent gene regulation. *Elife* **2016**, *5*.
- (75) Lišková, R. Recombinant preparation of TEAD transcription factor: Diplomová práce PĚF UK Praha, katedra analytické chemie, 76 (2016).